Please login to the form below
Cabometyx
This page shows the latest Cabometyx news and features for those working in and with pharma, biotech and healthcare.
NICE publishes draft guidance not recommending Ipsen’s Cabometyx for thyroid cancer
The National Institute for Health and Care Excellence (NICE) has published draft guidance not recommending Ipsen’s Cabometyx (cabozantinib) for patients with differentiated thyroid cancer (DTC) who have either not responded ... The drug was approved
Latest news
-
BMS, Exelixis and Ipsen report three-year results for combination treatment in kidney cancer
Bristol Myers Squibb (BMS), Exelixis and Ipsen have reported positive three-year follow-up results from a phase 3 study of Opdivo (nivolumab) in combination with Cabometyx (cabozantinib) in advanced renal ... of the Cabometyx and Opdivo combination
-
European Commission approves Opdivo plus Cambometyx for advanced kidney cancer
Twice as many patients responded to Opdivo plus Cabometyx compared to Sutent – 55.7% and 27.1%, respectively. ... Opdivo/Cabometyx was also associated with a disease control rate of 88.2% versus 69.9% with Sutent.
-
New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer
Bristol Myers Squibb (BMS) and Exelixis also recently revealed new analyses from a phase 3 study of their Opdivo (nivolumab) and Cabometyx (cabozantinib) combination in first-line, advanced RCC. ... Opdivo/Cabometyx was also associated with a disease
-
BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer
Opdivo/Cabometyx was also associated with a disease control rate of 88.2% versus 69.9% with Sutent. ... The US Food and Drug Administration (FDA) has already approved Opdivo/Cabometyx for the first-line treatment of advanced RCC.
-
BMS gains FDA approval for second Opdivo combo in kidney cancer
The new Opdivo/Cabometyx approval is also for the first-line treatment of patients with advanced RCC. ... The European Medicines Agency (EMA) has already validated the completion of BMS/Exelixis’ submissions for Opdivo/Cabometyx in RCC, launching the
More from news
Approximately 11 fully matching, plus 10 partially matching documents found.
Latest Intelligence
-
Charting a course for expansion
The February deal, which gives Ipsen commercialisation and development rights outside the US, has seen Cabometyx take off rapidly. ... It showed that Cabometyx can decrease the rate of disease progression or death by 31% in advanced renal cell carcinoma
More from intelligence
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- AbbVie’s Rinvoq receives FDA approval for Crohn’s disease
- Bayer’s Nubeqa combination recommended by NICE to treat metastatic prostate cancer
- AstraZeneca announces positive phase 3 results for Tagrisso combination in lung cancer
- Novo Nordisk announces positive phase 3 results for oral weight-loss drug
- COVID-19: Pfizer’s Paxlovid approved by FDA and Gilead’s Veklury recommended by CHMP
- FDA approves Blueprint Medicines’ Ayvakit for indolent systemic mastocytosis
- Medscape Medical Affairs Selected as Finalist for 2023 Communiqué Awards
- COVID-19: Pfizer’s Paxlovid approved by FDA and Gilead’s Veklury recommended by CHMP
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Gene therapy, gene editing and perspectives on future use in Parkinson’s disease
- Patient Clinical Trial & Communications Plan Review: A Customer Story
- Shining a Spotlight on Women’s Health Education Outcomes at ACOG 2023
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- Patient Clinical Trial & Communications Plan Review: A Customer Story
- ...
- Working together to achieve better patient pathways
- Digital tools can supercharge patient treatment and outcomes but the importance of the patient voice cannot be underestimated...
- Design-thinking. Iterating for continuous improvement.
- How design can lead improvement within Pharma...
